Purchases on pharma at Piazza Affari, Recordati and DiaSorin rise

(Il Sole 24 Ore Radiocor) - Well-bought in Piazza Affari pharma stocks, which have been performing in the red since the start of the year. In particular, Recordati and Diasorin, with the former losing about 3% since the start of the year and the latter plummeting more than 37% (with a heavy slide in November, following the guidance revision), compared with a FTSE MIB up more than 27%.

For Recordati, which had reached a high of 60.95 euro in February, worth mentioning are two internal dealing transactions, with the chairman Andrea Recordati buying 21,050 shares at 47.4949 euro for almost 1 mln euro and the outgoing cfo Luigi La Corte buying 4,000 shares at 48.5833 euro for a total value of about 194,000 euro.

On the other hand, with regard to DiaSorin, far from the highs reached in the Covid period (over 209 euro), analysts look to the Budget Law that recognises pharmacies as health care delivery structures, with services permanently integrated into the SSN. "The ongoing evolution reflects the growing trend of decentralisation of diagnostics, not only in the US but also in Europe and Italy," they underline at Intermonte (neutral, with a target price of 82 euro), "with the affirmation of high-performance point-of-care platforms, such as Liaison Nes by DiaSorin and Spotfire by bioMérieux, designed to offer rapid and reliable analyses closer to the patient".

For the launch of Liaison Nes, the roadmap envisages a regulatory clearance in the US between late 2025 and early 2026, and the preparation of the launch and distribution network during the first half of 2026, with the first contribution in terms of sales in the second half. "We expect from Liaison Nes a modest contribution," they say from Intermonte, "of around 25 mln in 2027, despite the excellent commercial response recorded by bioMérieux with Spotfire, launched at the end of 2023, which is expected to reach sales of 170 mln this year (around 4% of revenues), after having totalled 110 mln in the 9 months of 2025. With Spotfire, BioMérieux aims to reach a turnover of about 450 mln by 2028 (about 9% of revenues), 5 years after launch.